drugset / Trial / NCT01290328

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation

NCT01290328

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the effect of Epoetin Alfa (Procrit) on the change in hemoglobin (red blood cell count) in anemic kidney transplant recipients. The investigators hypothesize that epoetin alfa will raise hemoglobin.

Timeline

Start
2011-02
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 150 iu/kg

Indications